June 24, 2022
No answers anytime soon for the questions on when will inflation peak, how soon will we see a recession, and how high will the Fed raise rates?
Pre-open indications, 2 Negative Indications, 4 SELLs into Strength and 1 Puff/Pump/Promote
RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
The 7:30 A.M., ET edition
June 23, 2022
Very lucky, BSTG settled terminal death suit as Dr. Paolo Macchiarini was found criminally liable in Swedish court for causing felony bodily injury to a patient, he had fitted with one of the artificial windpipes.
With a three (3) year-old IND and multiple, and more Private Placements (PPM) that have funded WHAT?
Who or whom U.S. investors invest in this equity are backing the wrong horse or just putting lipstick on a pig?
Where did it all start; with CEO and founder David Green "ensnaring and entangling" BSTG with a terminal death suit “supplying” Paolo Macchiarini; an Italian doctor who made headlines for pioneering windpipe surgery has gone on trial in Sweden, charged with aggravated assault for performing the experimental procedure.
June 24, 2022
As investors exit upcoming and present risks
Pre-open indications: 6 HITs
WHY and HOW is this market affecting the cell and gene therapy sector … “The Bottom Line” underlines the framework of share pricing actions. Who else is tracking a broad grouping of cell and gene therapy equities – can you afford to not read facts supported by real numbers?
It’s a quick read to understand the ebb and flow of the session in one site
The week in review - what happened and to whom, the root metrics
June 23, 2022
Very lucky, BSTG settled terminal death suit as Dr. Paolo Macchiarini was found criminally liable in Swedish court for causing felony bodily injury to a patient, he had fitted with one of the artificial windpipes. With a three (3) year-old IND and multiple, and more Private Placements (PPM) that have funded WHAT? Who or whom U.S. investors invest in this equity are backing the wrong horse or just putting lipstick on a pig? Where did it all start; with CEO and founder David Green "ensnaring and entangling" BSTG with a terminal death suit “supplying” Paolo Macchiarini; an Italian doctor who made headlines for pioneering windpipe surgery has gone on trial in Sweden, charged with aggravated assault for performing the experimental procedure.
June 2, 2022
KDNY priced (5/24/22) its underwritten public offering of 6,428,572 shares of its common stock at a price to the public of $14.00 per share. On 6/2/22, KDNY is trading at +$0.66 to $16.29 after trading 5/24/22 at $15.11
June 2, 2022
A scorecard of earnings releases of covered companies - 32 of 35 - so far The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status". Added Mesoblast (MESO) - this week
June 24, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector gets a spanking
June 24, 2022
RegMed Investors’ (RMi) pre-open: Sell the risk, earnings are coming
June 23, 2022
The Biostage (BSTG) Chronicles: filed an S-1 preliminary offering prospectus by Newbridge Securities Corporation.
June 23, 2022
RegMed Investors’ (RMi) closing bell: which way forward? SELL into Strength, come back post earnings
June 23, 2022
RegMed Investors’ (RMi) pre-open: as share pricing recognition responds, fear still lingers
June 22, 2022
RegMed Investors’ (RMi) closing bell: cell and gene therapy sector rises as indexes stumble
June 22, 2022
RegMed Investors’ (RMi) pre-open: Expectation bucks into sustainability
June 21, 2022
RegMed Investors’ (RMi) closing bell: sector boomed today, what’s sustainable and for how long?
© 2022 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
